NASDAQ · RDHL
Healthcare · Drug Manufacturers - Specialty & Generic
$0.61
Down-$0.02 (-3.94%)
Updated Aug 25, 2026, 10:37 AM
SID Score
2.8/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance
1M range · 21 trading sessions · Daily adjusted prices
RDHL closed at $0.61 after 21 trading sessions, down 13.54% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Aug 24, 2026 | $0.6376 | $0.6376 | $0.6022 | $0.6052 | 11.94K |
| Aug 21, 2026 | $0.612 | $0.65 | $0.60 | $0.63 | 19.48K |
| Aug 20, 2026 | $0.62 | $0.65 | $0.62 | $0.6251 | 15.44K |
| Aug 19, 2026 | $0.5804 | $0.6329 | $0.5804 | $0.628 | 25.49K |
| Aug 18, 2026 | $0.5801 | $0.602 | $0.57 | $0.5929 | 39.65K |
| Aug 17, 2026 | $0.60 | $0.6099 | $0.582 | $0.585 | 31.97K |
| Aug 14, 2026 | $0.585 | $0.6043 | $0.5801 | $0.5999 | 8.51K |
| Aug 13, 2026 | $0.581 | $0.6298 | $0.5807 | $0.595 | 25.42K |
| Aug 12, 2026 | $0.6105 | $0.6198 | $0.5809 | $0.59 | 21.34K |
| Aug 11, 2026 | $0.62 | $0.6419 | $0.5902 | $0.60 | 11.53K |
| Aug 10, 2026 | $0.6049 | $0.6496 | $0.581 | $0.581 | 47.83K |
| Aug 7, 2026 | $0.648 | $0.648 | $0.5817 | $0.605 | 54.41K |
| Aug 6, 2026 | $0.68 | $0.68 | $0.5799 | $0.581 | 58.69K |
| Aug 5, 2026 | $0.6302 | $0.6752 | $0.6302 | $0.67 | 22.74K |
| Aug 4, 2026 | $0.67 | $0.6994 | $0.6338 | $0.6479 | 18.41K |
| Aug 3, 2026 | $0.65 | $0.6567 | $0.6484 | $0.6502 | 21.46K |
| Jul 31, 2026 | $0.6867 | $0.6867 | $0.6351 | $0.65 | 12.37K |
| Jul 30, 2026 | $0.6831 | $0.7094 | $0.63 | $0.6307 | 64.99K |
| Jul 29, 2026 | $0.701 | $0.715 | $0.661 | $0.6828 | 95.9K |
| Jul 28, 2026 | $0.72 | $0.73 | $0.65 | $0.73 | 123.27K |
| Jul 27, 2026 | $0.65 | $0.7099 | $0.65 | $0.70 | 27.74K |
The latest Smart Investors Daily articles mentioning RDHL.
RDHL research
Company profile and research snapshot.
Redhill Biopharma Ltd is a specialty biopharmaceutical company focused on gastrointestinal diseases. The company is dedicated to advancing its development pipeline of clinical-stage therapeutic candidates. It also commercializes GI-related products in the U.S., including Talicia (omeprazole, amoxicillin, and rifabutin) and Aemcolo (rifamycin). Currently, the company's pipeline consists of five therapeutic candidates: Opaganib, RHB-107, RHB-102, RHB-204, and RHB-104, the majority of which are in clinical development.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Sep 15, 2021 | HC Wainwright & Co. | Buy | — |
| Aug 31, 2021 | Cantor Fitzgerald | Overweight | — |
| May 28, 2021 | WBB Securities | Buy | — |
| May 18, 2021 | HC Wainwright & Co. | Buy | — |
| Sep 11, 2020 | BTIG | Buy | — |
No generated briefing is available yet.
Benzinga · Aug 12, 2026
Gainers ENvue Medical (NASDAQ:FEED) shares rose 49.1% to $0.61 during Wednesday's after-market session. The market value of their outstanding shares is at $2.4 million. Omeros (NASDAQ:OMER) stock moved upwards by
Benzinga · Jun 18, 2026
RedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced that it has entered into a definitive agreement for the purchase and sale of an aggregate of
Benzinga · Jun 15, 2026
Benzinga · Jun 9, 2026
The U.S. Food and Drug Administration (FDA) has granted rare pediatric disease designation to opaganib1 for the treatment of neuroblastoma, a type of cancer most commonly affecting babies and young children--Rare
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning RDHL.
No results
No recent SID articles mention RDHL.
